Developer docs
API playgroundTry for free, no card

Search company profiles

Phathom Pharmaceuticals

Full company profile

uuid0000nlb

Namestring
Phathom Pharmaceuticals
Legal namestring
Phathom Pharmaceuticals, LLC
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Phathom Pharmaceuticals is a US-based, publicly traded (NASDAQ: PHAT) specialty biopharmaceutical company founded in 2018 and headquartered in Florham Park, New Jersey, with R&D operations in Buffalo Grove, Illinois. The company is built around a single asset: vonoprazan, a small-molecule Potassium-Competitive Acid Blocker (PCAB) licensed from Takeda, marketed in the United States as VOQUEZNA. VOQUEZNA is the first FDA-approved PCAB for GERD, offering rapid and sustained acid suppression for erosive esophagitis and non-erosive reflux disease (NERD) without requiring the acid activation step characteristic of proton pump inhibitors (PPIs). The company also markets VOQUEZNA Triple Pak and VOQUEZNA Dual Pak as combination therapies for Helicobacter pylori eradication, addressing rising antibiotic resistance in a condition affecting roughly 35% of the US population.

The core technology, vonoprazan, reversibly inhibits the hydrogen-potassium ATPase enzyme in gastric parietal cells, providing rapid onset, dose-dependent, and sustained 24-hour acid suppression. Phathom is currently running the Phase 2 pHalcon-EoE-201 trial, the first large placebo-controlled study of an acid suppression therapy for eosinophilic esophagitis, signaling pipeline diversification beyond the approved indications. Regulatory exclusivity extends through May 2032 with potential extensions to 2033-2034.

The business model is a classic single-asset specialty pharma model: product revenue is generated from wholesale distribution through authorized distributors of record (ADRs) and commercialized via a field sales force of 290+ representatives targeting gastroenterologists, Advanced Practice Practitioners (APPs), and select primary care physicians. Pricing follows standard unit (WAC) pricing under US statuary disclosure regimes. Revenue scaled from $55.3M in FY2024 to $175.1M in FY2025 (217% growth) with 85% gross margins, and management has guided to $320-$345M for FY2026. The customer base is fragmented across thousands of prescribers with no large anchor accounts, but the company's revenue is concentrated in a single molecule and product family. Phathom supplements its dilutive and non-dilutive financing (over $540M raised in equity, plus a $175M Hercules term loan and $300M revenue interest facility) to fund the path to operating profitability targeted for Q3 2026 and positive cash flow in 2027.

Short descriptiontext

Phathom Pharmaceuticals is a US biopharmaceutical company that commercializes VOQUEZNA (vonoprazan), the first FDA-approved PCAB for GERD and H. pylori eradication, selling through a 290+ rep specialty sales force targeting gastroenterologists and expanding into primary care.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersFlorham Park, United States
HQ citystring
Florham Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gastrointestinal therapeutics, acid suppression therapy, potassium-competitive acid blockers, H. pylori eradication, GERD treatment drugs
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Gastroenterology Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1VOQUEZNA (vonoprazan) Prescription Drug Sales
TypeOne Time License
Description

Phathom generates revenue from the sale of its FDA-approved drug VOQUEZNA for treatment of GERD (erosive esophagitis and non-erosive reflux disease) and related conditions. The company also sells VOQUEZNA Triple Pak and VOQUEZNA Dual Pak for H. pylori eradication. Revenue has grown significantly: Q1 2026 net revenues of $58.3 million (104% year-over-year growth), with full-year 2025 revenue of $175.1 million (217% year-over-year growth).

fool.com
2Stock Offerings and Equity Financing
TypeHardware Sales
Description

The company has raised capital through multiple public stock offerings: August 2024 ($130 million), January 2026 ($130 million), and June 2023 ($150.3 million). These are dilutive financing events to fund commercialization and clinical development.

globenewswire.com
3Revenue Interest Financing
TypeLicensing Royalties
Description

Non-dilutive capital secured from investors under revenue interest financing agreements, tied to FDA approvals and sales milestones. Total available funding increased to $300 million including an additional $40 million secured in 2022.

globenewswire.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain
Pricing details3 tiers
1VOQUEZNA (vonoprazan) for GERD treatment
ModelUnit PricingBilling cadencePay-as-you-go
Notes

WAC pricing disclosed per state requirements for California prescribers as required by California Health & Safety Code. Pricing information available via Connecticut WAC Disclosure Form.

phathompharma.com
2VOQUEZNA Triple Pak and Dual Pak for H. pylori
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Colorado WAC disclosure form available for VOQUEZNA, VOQUEZNA Triple Pak, and VOQUEZNA Dual Pak per Colorado Revised Statutes requirements.

phathompharma.com
3VOQUEZNA brand products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Connecticut WAC disclosure form available for VOQUEZNA, VOQUEZNA Triple Pak, and VOQUEZNA Dual Pak per Connecticut House Bill No. 6669.

phathompharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1VOQUEZNA
Description

FDA-approved potassium-competitive acid blocker (PCAB) for treatment of GERD and H. pylori infection

phathompharma.com
+2 more records
Core offering1 text field

Phathom Pharmaceuticals develops and commercializes FDA-approved prescription drugs based on vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Its commercial portfolio consists of VOQUEZNA tablets for erosive esophagitis and non-erosive GERD, plus VOQUEZNA Triple Pak and VOQUEZNA Dual Pak combination therapies for H. pylori eradication. The products are sold in the United States under exclusive license from Takeda.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 150% year-over-year revenue growth to $205 million trailing twelve months
+5 more records
Product overview1 text field

Phathom Pharmaceuticals offers a focused portfolio of three FDA-approved products centered on its novel potassium competitive acid blocker (PCAB), vonoprazan, marketed as VOQUEZNA. The portfolio includes VOQUEZNA (vonoprazan) for the treatment of erosive and non-erosive GERD, along with two combination therapy packs (VOQUEZNA Triple Pak and VOQUEZNA Dual Pak) designed for H. pylori eradication treatment. All three products utilize the same active ingredient (vonoprazan) but are formulated and packaged differently to address distinct gastrointestinal conditions.

Product and service3 records
1VOQUEZNA (vonoprazan)
CategoryGastroenterology Prescription Drug
Description

FDA-approved potassium-competitive acid blocker (PCAB) tablet for the treatment of erosive GERD (erosive esophagitis) and non-erosive GERD (NERD) in adults, providing rapid and sustained 24-hour acid suppression. Marketed in the United States and prescribed primarily by gastroenterologists and APPs.

2VOQUEZNA Triple Pak
CategoryGastroenterology Prescription Drug
Description

Combination therapy pack containing vonoprazan tablets, amoxicillin capsules, and clarithromycin tablets for the treatment of H. pylori infection in adults. FDA-approved co-packaged regimen.

3VOQUEZNA Dual Pak
CategoryGastroenterology Prescription Drug
Description

Combination therapy pack containing vonoprazan tablets and amoxicillin capsules for the treatment of H. pylori infection in adults. FDA-approved co-packaged regimen offering a dual-therapy alternative.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major pharma with established GI franchise (Creon, LINZESS via the Allergan acquisition) and deep commercial infrastructure in the gastroenterology specialist channel that Phathom targets.

TypeEmerging player
Description

Smaller specialty GI company commercializing Talicia (H. pylori eradication) and Aemcolo, directly competing in the H. pylori treatment space where Phathom sells VOQUEZNA Triple Pak and Dual Pak.

TypeBroad incumbent
Description

Specialty GI business (Xifaxan, Relistor) built on a similar model of dedicated GI field sales and specialist-focused commercialization, ultimately sold to Bausch Health for ~$11B; provides a precedent for the value a specialty GI franchise can capture.

TypeEmerging player
Description

Single-asset specialty GI company commercializing GIMOTI (metoclopramide nasal spray) for diabetic gastroparesis. Comparable small commercial-stage GI company with concentrated field sales and prescriber focus.

TypeOthers
Description

Large generic manufacturer that markets generic omeprazole and other PPIs in the US, including authorized generics of leading acid suppressors; relevant as the structural backdrop of cheap PPI competition that Phathom must overcome.

TypeBroad incumbent
Description

Original licensor of vonoprazan to Phathom and major global GI player (ENTYVIO for IBD, Dexilant). Provides a useful reference for the long-term global value of a leading acid-suppression franchise.

TypeDirect peer
Description

Specialty GI biopharma commercializing IBSRELA (tenapanor) for IBS-C and XPHOZAH for hyperphosphatemia. Comparable small-cap commercial-stage GI company targeting similar specialist prescriber bases.

TypeBroad incumbent
Description

Created and previously commercialized Nexium (esomeprazole), the leading PPI that VOQUEZNA is designed to disrupt. Useful benchmark for the trajectory of an acid-suppression blockbuster through genericization.

TypeDirect peer
Description

Specialty GI biopharma commercializing LINZESS (linaclotide) for IBS-C/CIC. Closest US-listed peer in terms of single-franchise specialty GI model, prescriber targeting, and revenue scale trajectory.

TypeBroad incumbent
Description

Previously commercialized Protonix (pantoprazole), another leading PPI. Provides a comparison point for the commercial scale and eventual commoditization of a PPI franchise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phathom Pharmaceuticals

Gastroenterology Pharmaceuticalsphathompharma.com

Phathom Pharmaceuticals is a US biopharmaceutical company that commercializes VOQUEZNA (vonoprazan), the first FDA-approved PCAB for GERD and H. pylori eradication, selling through a 290+ rep specialty sales force targeting gastroenterologists and expanding into primary care.

What Phathom Pharmaceuticals does

Phathom Pharmaceuticals is a US-based, publicly traded (NASDAQ: PHAT) specialty biopharmaceutical company founded in 2018 and headquartered in Florham Park, New Jersey, with R&D operations in Buffalo Grove, Illinois. The company is built around a single asset: vonoprazan, a small-molecule Potassium-Competitive Acid Blocker (PCAB) licensed from Takeda, marketed in the United States as VOQUEZNA. VOQUEZNA is the first FDA-approved PCAB for GERD, offering rapid and sustained acid suppression for erosive esophagitis and non-erosive reflux disease (NERD) without requiring the acid activation step characteristic of proton pump inhibitors (PPIs). The company also markets VOQUEZNA Triple Pak and VOQUEZNA Dual Pak as combination therapies for Helicobacter pylori eradication, addressing rising antibiotic resistance in a condition affecting roughly 35% of the US population.

The core technology, vonoprazan, reversibly inhibits the hydrogen-potassium ATPase enzyme in gastric parietal cells, providing rapid onset, dose-dependent, and sustained 24-hour acid suppression. Phathom is currently running the Phase 2 pHalcon-EoE-201 trial, the first large placebo-controlled study of an acid suppression therapy for eosinophilic esophagitis, signaling pipeline diversification beyond the approved indications. Regulatory exclusivity extends through May 2032 with potential extensions to 2033-2034.

The business model is a classic single-asset specialty pharma model: product revenue is generated from wholesale distribution through authorized distributors of record (ADRs) and commercialized via a field sales force of 290+ representatives targeting gastroenterologists, Advanced Practice Practitioners (APPs), and select primary care physicians. Pricing follows standard unit (WAC) pricing under US statuary disclosure regimes. Revenue scaled from $55.3M in FY2024 to $175.1M in FY2025 (217% growth) with 85% gross margins, and management has guided to $320-$345M for FY2026. The customer base is fragmented across thousands of prescribers with no large anchor accounts, but the company's revenue is concentrated in a single molecule and product family. Phathom supplements its dilutive and non-dilutive financing (over $540M raised in equity, plus a $175M Hercules term loan and $300M revenue interest facility) to fund the path to operating profitability targeted for Q3 2026 and positive cash flow in 2027.

Phathom Pharmaceuticals firmographics

Firmographics
Name
Phathom Pharmaceuticals
Legal name
Phathom Pharmaceuticals, LLC
Website
https://phathompharma.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
251–500 employees
Short description
Phathom Pharmaceuticals is a US biopharmaceutical company that commercializes VOQUEZNA (vonoprazan), the first FDA-approved PCAB for GERD and H. pylori eradication, selling through a 290+ rep specialty sales force targeting gastroenterologists and expanding into primary care.
Ownership category
akta.pro rank

Phathom Pharmaceuticals industry classification

Industry
Product category
Gastroenterology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Gastrointestinal therapeutics
  • Acid suppression therapy
  • Potassium-competitive acid blockers
  • H. pylori eradication
  • GERD treatment drugs

Where Phathom Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Florham Park
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Phathom Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Operations, Technology or R&D, Supply Chain

Revenue model

  1. VOQUEZNA (vonoprazan) Prescription Drug Sales: Phathom generates revenue from the sale of its FDA-approved drug VOQUEZNA for treatment of GERD (erosive esophagitis and non-erosive reflux disease) and related conditions. The company also sells VOQUEZNA Triple Pak and VOQUEZNA Dual Pak for H. pylori eradication. Revenue has grown significantly: Q1 2026 net revenues of $58.3 million (104% year-over-year growth), with full-year 2025 revenue of $175.1 million (217% year-over-year growth).
  2. Stock Offerings and Equity Financing: The company has raised capital through multiple public stock offerings: August 2024 ($130 million), January 2026 ($130 million), and June 2023 ($150.3 million). These are dilutive financing events to fund commercialization and clinical development.
  3. Revenue Interest Financing: Non-dilutive capital secured from investors under revenue interest financing agreements, tied to FDA approvals and sales milestones. Total available funding increased to $300 million including an additional $40 million secured in 2022.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goVOQUEZNA (vonoprazan) for GERD treatment
Unit PricingPay-as-you-goVOQUEZNA Triple Pak and Dual Pak for H. pylori
Unit PricingPay-as-you-goVOQUEZNA brand products

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Phathom Pharmaceuticals product offering

Product offering

Core offering

Phathom Pharmaceuticals develops and commercializes FDA-approved prescription drugs based on vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Its commercial portfolio consists of VOQUEZNA tablets for erosive esophagitis and non-erosive GERD, plus VOQUEZNA Triple Pak and VOQUEZNA Dual Pak combination therapies for H. pylori eradication. The products are sold in the United States under exclusive license from Takeda.

Product overview

Phathom Pharmaceuticals offers a focused portfolio of three FDA-approved products centered on its novel potassium competitive acid blocker (PCAB), vonoprazan, marketed as VOQUEZNA. The portfolio includes VOQUEZNA (vonoprazan) for the treatment of erosive and non-erosive GERD, along with two combination therapy packs (VOQUEZNA Triple Pak and VOQUEZNA Dual Pak) designed for H. pylori eradication treatment. All three products utilize the same active ingredient (vonoprazan) but are formulated and packaged differently to address distinct gastrointestinal conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • VOQUEZNA: FDA-approved potassium-competitive acid blocker (PCAB) for treatment of GERD and H. pylori infection
  • VOQUEZNA Triple Pak
  • VOQUEZNA Dual Pak

Products and services

  • VOQUEZNA (vonoprazan) FDA-approved potassium-competitive acid blocker (PCAB) tablet for the treatment of erosive GERD (erosive esophagitis) and non-erosive GERD (NERD) in adults, providing rapid and sustained 24-hour acid suppression. Marketed in the United States and prescribed primarily by gastroenterologists and APPs.
  • VOQUEZNA Triple Pak Combination therapy pack containing vonoprazan tablets, amoxicillin capsules, and clarithromycin tablets for the treatment of H. pylori infection in adults. FDA-approved co-packaged regimen.
  • VOQUEZNA Dual Pak Combination therapy pack containing vonoprazan tablets and amoxicillin capsules for the treatment of H. pylori infection in adults. FDA-approved co-packaged regimen offering a dual-therapy alternative.

Quantifiable outcome

  • 150% year-over-year revenue growth to $205 million trailing twelve months
  • +5 more outcomes

Companies that use Phathom Pharmaceuticals

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Phathom Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Phathom Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators16 records

Recent moves7 records

Expansion highlights5 records

Phathom Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Major pharma with established GI franchise (Creon, LINZESS via the Allergan acquisition) and deep commercial infrastructure in the gastroenterology specialist channel that Phathom targets.
  • Salix Pharmaceuticals (Bausch Health): Specialty GI business (Xifaxan, Relistor) built on a similar model of dedicated GI field sales and specialist-focused commercialization, ultimately sold to Bausch Health for ~$11B; provides a precedent for the value a specialty GI franchise can capture.
  • Takeda Pharmaceutical: Original licensor of vonoprazan to Phathom and major global GI player (ENTYVIO for IBD, Dexilant). Provides a useful reference for the long-term global value of a leading acid-suppression franchise.
  • AstraZeneca: Created and previously commercialized Nexium (esomeprazole), the leading PPI that VOQUEZNA is designed to disrupt. Useful benchmark for the trajectory of an acid-suppression blockbuster through genericization.
  • Pfizer: Previously commercialized Protonix (pantoprazole), another leading PPI. Provides a comparison point for the commercial scale and eventual commoditization of a PPI franchise.

Emerging players

  • RedHill Biopharma: Smaller specialty GI company commercializing Talicia (H. pylori eradication) and Aemcolo, directly competing in the H. pylori treatment space where Phathom sells VOQUEZNA Triple Pak and Dual Pak.
  • Evoke Pharma: Single-asset specialty GI company commercializing GIMOTI (metoclopramide nasal spray) for diabetic gastroparesis. Comparable small commercial-stage GI company with concentrated field sales and prescriber focus.

Others

  • Dr. Reddy's Laboratories: Large generic manufacturer that markets generic omeprazole and other PPIs in the US, including authorized generics of leading acid suppressors; relevant as the structural backdrop of cheap PPI competition that Phathom must overcome.

Direct peers

  • Ardelyx: Specialty GI biopharma commercializing IBSRELA (tenapanor) for IBS-C and XPHOZAH for hyperphosphatemia. Comparable small-cap commercial-stage GI company targeting similar specialist prescriber bases.
  • Ironwood Pharmaceuticals: Specialty GI biopharma commercializing LINZESS (linaclotide) for IBS-C/CIC. Closest US-listed peer in terms of single-franchise specialty GI model, prescriber targeting, and revenue scale trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Phathom Pharmaceuticals social profiles

Digital presence

Phathom Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phathom Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles18 records

Phathom Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phathom Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phathom Pharmaceuticals

What does Phathom Pharmaceuticals do?

Phathom Pharmaceuticals develops and commercializes FDA-approved prescription drugs based on vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Its commercial portfolio consists of VOQUEZNA tablets for erosive esophagitis and non-erosive GERD, plus VOQUEZNA Triple Pak and VOQUEZNA Dual Pak combination therapies for H. pylori eradication. The products are sold in the United States under exclusive license from Takeda.

Is Phathom Pharmaceuticals a public or private company?

Phathom Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Phathom Pharmaceuticals founded?

Phathom Pharmaceuticals was founded in 2018. It employs 251 to 500 people.

Where is Phathom Pharmaceuticals based?

Phathom Pharmaceuticals is headquartered in Florham Park, United States, in the North America region.

How does Phathom Pharmaceuticals make money?

Three revenue lines are on record. VOQUEZNA (vonoprazan) Prescription Drug Sales are the primary driver. The others are stock Offerings and Equity Financing and revenue Interest Financing.

Who are Phathom Pharmaceuticals's main competitors?

Broad incumbents on record are AbbVie, Salix Pharmaceuticals (Bausch Health), Takeda Pharmaceutical, AstraZeneca and Pfizer. Emerging players are RedHill Biopharma and Evoke Pharma. Dr. Reddy's Laboratories is listed as an others. Direct peers are Ardelyx and Ironwood Pharmaceuticals.

Does Phathom Pharmaceuticals have an API?

No public API is recorded for Phathom Pharmaceuticals.

What industry is Phathom Pharmaceuticals in?

Phathom Pharmaceuticals's product category is Gastroenterology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeNew Analyst Forecast: $PHAT Given $10 Price Target | PHAT Stock NewsBarclays analyst Glen Santangelo set a $10 price target for PHAT on 11/18/2026. PHAT reported Q3 2026 revenue of $84.7M, up 71.14% year-over-year. Hedge fund activity shows 92 institutions added shares while 94 reduced positions in the most recent quarter.TradingViewBarclays maintains Phathom Pharmaceuticals at Overweight, lowers price target to $10 from $14Barclays maintained Phathom Pharmaceuticals at Overweight and lowered its price target to $10 from $14, a 28.6% decrease. The target implies an upside of 81.8% from the Nov 17 close of $5.50.Seeking AlphaPhathom Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:PHAT) 2026-11-02Phathom Pharmaceuticals reported Q3 2026 EPS of $0.04, beating by $0.01, while revenue of $84.72M missed by $100.40K. Revenue growth of 71.14% YoY was reported, with the company's stock closing at $5.92.MarketBeatPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock Has Average Price Target of $20.11 According to BrokeragesPhathom Pharmaceuticals has an average analyst rating of Moderate Buy with a 1-year price target of $20.11. Institutional investors own 99.01% of the stock, with several funds increasing positions in Q3. The company develops Voquezna for gastrointestinal diseases.MarketBeatWhat Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings CallPhathom Pharmaceuticals reported Q3 2026 revenue of $84.7 million, up 71% year-over-year, and a second consecutive quarter of positive operating profit excluding stock-based compensation. The company maintained its full-year 2026 revenue guidance of $310 million to $325 million and expects durable positive cash flow in 2027.MarketBeatWhat Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings CallPhathom Pharmaceuticals reported Q3 2026 net revenue of $84.7 million, up 71% year-over-year, and positive operating profit excluding stock-based compensation of $5.8 million. The company maintained its full-year 2026 revenue guidance of $310 million to $325 million and expects durable positive cash flow in 2027.MarketBeatPhathom Pharmaceuticals (NASDAQ:PHAT) Announces Quarterly Earnings ResultsPhathom Pharmaceuticals reported Q3 EPS of $0.04, beating the $0.11 consensus, with revenue of $84.72 million versus an $84.82 million estimate. The company raised Q3 revenue 71% year over year and maintained its 2026 revenue guidance of $310–325 million. It expects Phase II pHalcon-EoE data in Q4 2026.Seeking AlphaPhathom Pharmaceuticals Non-GAAP EPS of $0.04 beats by $0.01, revenue of $84.7M misses by $0.12M (PHAT:NASDAQ)Phathom Pharmaceuticals reported Q3 non-GAAP EPS of $0.04, beating by $0.01, while revenue of $84.7M missed by $0.12M. Cash and equivalents totaled $184.6M at September 30, 2026. The company reaffirmed FY2026 net revenue guidance of $310M–$325M.The future of tradingPhathom Pharmaceuticals Q3 2026 net revenues climb 71% year over year to $84.7 millionPhathom Pharmaceuticals reported Q3 2026 net revenues of $84.7 million, up 71% year over year. Operating profit excluding stock-based compensation remained positive for a second consecutive quarter, and net cash generated totaled $2.1 million. The company reaffirmed its 2026 net revenues guidance of $310 million to $325 million.The future of tradingPhathom Maintains 2026 Net Revenue Forecast of $310 Million-$325 MillionPhathom Pharmaceuticals maintained its 2026 net revenue guidance of $310 million to $325 million, with operating expenses of $235 million to $245 million excluding stock-based compensation. Third-quarter 2026 net revenue reached $84.7 million, up about 71% year-over-year. The company expects operating profitability for the remainder of 2026 and positive cash flow in 2027.